Abstract
Oral cancers are the most common cancer in India due to tobacco abuse in the form of chewing, smoking, and inhalation. Majority of these patients present late at advanced disease stage. Such patients have significant morbidity irrespective of the intent of treatment; the survival rate is very poor. To improve loco-regional control and survival, neoadjuvant chemotherapy has been started in many centers all over the world. To study the effect of injecting methotrexate as a single agent in (1) down-staging and increasing operability of oral cancers, (2) need for reconstructive surgery, and (3) recurrence. A total of 50 patients with biopsy-proven oral malignancy were selected over a period of 2 years from August 2014 to August 2016 for the study. Patients were subjected to weekly dose of injecting methotrexate 1 mg/kg given intravenously for 6 weeks. All patients underwent surgery after completing 6 cycles of methotrexate. A total 50 patients were started on inj. methotrexate of which 9 patients did not complete neoadjuvant chemotherapy. 53.7% of patients showed more than 50% decrease in tumor size. 29.26% of patients showed complete disappearance of cervical lymph nodes and 31.7% of patients showed more than 50% decrease in size of cervical lymph nodes. 48.78% of patients were managed with wide local excision with primary closure, decreasing the need of reconstructive surgery. 94.74% of patients did not show any recurrence in follow-up period of 1 year. Single agent methotrexate is effective in down-staging oral cancers, improving operability and decreasing morbidity and recurrence among patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Mehrotra R, Gupta A, Singh M, Ibrahim R (2006) Application of cytology and molecular biology in diagnosing premalignant and malignant oral lesions. Mol Cancer 5(11):476–498
Mishra V, Singh PA, Lal NA, Agarwal P, Singh M (2009) Changing patterns of oral cavity lesions and personal habits over a decade: hospital based record analysis from Allahabad. Indian J Community Med 34(4):321–325
Ahluwalia H, Gupta SC, Singh M, Mishra V, Singh PAWDK Spectrum of head and neck malignancies in Allahabad. Indian J Otolaryngol Head Neck Surgery 53(1):16–21
Kademani D Oral cancer. Mayo Clinic 4174:878–887
Siegel R, Naishadham D, Jemal A (2012) Cancer Statistatics, 2012. Ca Cancer J Clin 62:10–29
Neville BW, Day T (2002) Oral cancer precancerous lesions. CA Cancer J Clin 52:195–215
Parkin DM, Bray F, Ferlay J, Pisani P (2005) Glob cancer stat 2002. CA Cancer J Clin 55:74–108
National comprehensive cancer network; NCCN Clinical practice guidelines in oncology; Head and neck cancer version. 2012 https://www.nccn.org/professionals/physician_gls/default.aspx
Pathak KA, Gupta S, Talole S, Khanna V, Chaturvedi P, Deshpande MS et al (2005) Advanced squamous cell carcinoma of lower gingivobuccal complex: patterns of spread and failure. Head Neck 27:597–602
EI-Sayed s NN (1996) Adjuvant and adjunctive chemotherapy in management of squamous cell carcinoma of head and neck region. A meta-analysis of prospective and randomised trial. J Clin Oncol 14:838–847
Brockstein BEVE (2006) Principle of chemotherapy in management of head and neck cancer in head and neck surgery-otolaryngology, Bailey BJ, Johnson JT, Newlands SD. Lippincott Williams & Wilkins; pp 357–72
Deconth RCSD (1981) A randomised prospective comparison of intermittent methotrexate, methotrexate with leucovorin, and methotrexate combination in head and neck cancer. Int J Radiat Oncol Biol Phys 48:1061–1072
Freeman-Narrod M, Gerstley BJEP (1975) Comparison of serum concentrations of methotrexate after various routes of administration. Cancer 36:1619–1624
Kremer JMLJ (1986) The safety and efficacy of the use of methotrexate in long term therapy for rheumatoid arthritis. Arthritis Rheum 29:822–831
Kohno N, Ikori T, Kawaida M, Tanaka K, Kawaura MK et al (2000) Survival results of neoadjuvant chemotherapy for advanced squamous cell carcinoma of head and neck. Jpn J Clin Oncol 30:253–258
Ronald C, De Conti MD, Schoenfeld D (1981) Randomized prospective comparison of intermittent methotrexate, methotrexate with leucovorin, and a methotrexate combination in head and neck cancer. Am Cancer Soc 48:1072–1981
Specenier PM, Vermorken JB (2009) Current concepts for the management of head and neck cancer: chemotherapy. Oral Oncol 45:409–415
Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia RDM, Al E (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695–1704
Haddad RISD (2008) Recent advances in head and neck cancer. N Engl J Med 359:1143–1154
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Deshpande, A., Nandu, V.V. & Jadhav, J. Role of Single-Agent Methotrexate as a Neoadjuvant Chemotherapy in Oral Cavity Cancers. Indian J Surg Oncol 10, 125–129 (2019). https://doi.org/10.1007/s13193-018-0846-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13193-018-0846-3